Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beam TherapeuticsBEAM +1.95%71 Equity-to-Asset is 0.77 as of Jun. 2026, which is 15% above its 10-year median of 0.67. GuruFocus rates BEAM with a GF Score™ of 71/100 and a GF Value™ of $28.11 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Beam Therapeutics ranks better than 60.66% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Beam Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $1,067.4 Mil. Beam Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $1,386.4 Mil.
Therefore, Beam Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.77.
The historical rank and industry rank for Beam Therapeutics's Equity-to-Asset or its related term are showing as below:
BEAM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.74 Med: 0.67 Max: 0.84
Current: 0.77
During the past 9 years, the highest Equity to Asset Ratio of Beam Therapeutics was 0.84. The lowest was -1.74. And the median was 0.67.
BEAM's Equity-to-Asset is ranked better than 60.66% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs BEAM: 0.77
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Beam Therapeutics Equity-to-Asset Related Terms
Beam Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BEAM vs KOD, TARS, VERA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Beam Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Beam Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (BEAM) has a Equity-to-Asset of 0.77 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Beam Therapeutics and its competitors. This is 15% above median its historical median of 0.67. According to the industry distribution chart, Beam Therapeutics ranks #557 out of 1416 companies in the Biotechnology industry, placing it in the top 39.3%.
Is Beam Therapeutics' Equity-to-Asset too high?
Beam Therapeutics' current Equity-to-Asset of 0.77 is 15% above median its 10-year median of 0.67. The Biotechnology industry median Equity-to-Asset is 0.68. Beam Therapeutics' value of 0.77 is 13.2% above this industry median. Based on the distribution chart, Beam Therapeutics ranks #557 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Equity-to-Asset compare to KOD and TARS?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #557 out of 1416 companies for Equity-to-Asset. This puts Beam Therapeutics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Beam Therapeutics' value of 0.77 is 13.2% above this benchmark. While the company's 10-year median is 0.67 vs. the industry median of 0.68, Beam Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beam Therapeutics's current Equity-to-Asset of 0.77 is 13.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Beam Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beam Therapeutics's current Equity-to-Asset is 0.77, which is 15% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.77 — trading 1.2% below its estimated fair value. The current Equity-to-Asset is 0.77, which is 15% above median its 10-year median of 0.67 and 13.2% above the Biotechnology industry median of 0.68. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current Equity-to-Asset is 0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued.
The current stock price of $27.77 is trading 1.2% below its estimated GF Value™ of $28.11.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for BEAM:
Equity-to-Asset: 0.77 (15% above median its 10-year median of 0.67)
GF Value™: $28.11 vs. price of $27.77 (1.2% below fair value)
Industry Position: 13.2% above the Biotechnology median (#557 of 1416)
No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score
Get the complete analysis for BEAM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAM has been successfully added to your 
